Mouwasat Medical Services Co.

As of June 30, 2026, Mouwasat Medical Services Co. carries a market capitalization of 12.75B, placing it among publicly traded companies globally. Its enterprise value stands at 13.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mouwasat Medical Services Co.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Mouwasat Medical Services Co. has 200.00M shares outstanding.

As of June 30, 2026, Mouwasat Medical Services Co. trades at a trailing price-to-earnings ratio of 14.98. The price-to-sales ratio is 3.78, and the price-to-book ratio stands at 3.22.

As of June 30, 2026, Mouwasat Medical Services Co. trades at an EV/EBITDA multiple of 12.00 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.47 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Mouwasat Medical Services Co. trades at an EV/FCF ratio of 21.01, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 13.92B versus a market cap of 12.75B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Mouwasat Medical Services Co. maintains a current ratio of 1.51, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.76, indicating elevated leverage, while an interest coverage ratio of 60.88 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Mouwasat Medical Services Co. posted a return on equity (ROE) of 22.62, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 18.01 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 13.98, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.89, useful for judging operating efficiency across full business cycles. Inventory turnover of 7.47 indicates how many times Mouwasat Medical Services Co. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Mouwasat Medical Services Co. recorded 15.94M in income tax expense. That works out to an effective tax rate of 1.78, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 896.44M, leaving 850.41M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Mouwasat Medical Services Co.'s stock has declined approximately 27.45% over the past 52 weeks. The 50-day moving average sits at 63.17, while the 200-day moving average is 65.41.

Over the twelve months ended June 30, 2026, Mouwasat Medical Services Co. generated 3.37B in revenue and converted that into 850.41M in net income, yielding earnings per share of 4.41. EBITDA reached 1.16B, while operating income came in at 867.71M.

As of June 30, 2026, Mouwasat Medical Services Co. holds 158.99M in cash and equivalents against 1.18B in total debt, resulting in a net debt position of 950.48M. Total book value stands at 3.97B, with working capital of 621.11M providing operational flexibility.

Mouwasat Medical Services Co. produced 1.16B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -516.51M in capital expenditures, free cash flow totaled 643.77M - equivalent to 3.22 per share.

Over the twelve months ended June 30, 2026, Mouwasat Medical Services Co. posted a gross margin of 40.25, reflecting its pricing power and cost economics. The operating margin of 25.73 and net profit margin of 25.22 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Mouwasat Medical Services Co. paid dividends of 1.00 per share. The dividend payout ratio of 21.96 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.05, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.17, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Mouwasat Medical Services Co. shareholders.

Mouwasat Medical Services Co.'s most recent stock split took place on August 8, 2023 with a 1:2 split ratio.

As of June 30, 2026, Mouwasat Medical Services Co. has an Altman Z-Score of 4.43, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.